A pharmafood composition with cardiovascular protection function and a preparation method thereof

Abstract

The present application relates to the technical field of functional food, in particular to a kind of medicine-food homologous composition with cardiovascular function protection and a preparation method thereof.The composition includes radix puerariae, cassia seed, lotus leaf and cloud tuckahoe.The composition provided by the present application is all medicine-food homologous substance, mild in action, high in safety, and the present prescription takes ascending clear and descending turbid as the main idea, so that clear Yang can ascend, turbid Yin can descend, and phlegm-damp and fat turbidity can be removed.For people with phlegm-damp accumulation and turbid fat blockage, the present application has good conditioning effect, can improve blood lipid metabolism, and protect cardiovascular function.

Description

Technical Field

[0001] This invention relates to the field of functional food technology, and in particular to a food-medicine homology composition with cardiovascular protective function and its preparation method. Background Technology

[0002] With changing modern lifestyles, unhealthy habits such as high-fat diets, lack of exercise, and irregular sleep patterns are becoming increasingly common, leading to internal accumulation of phlegm and dampness, and obstruction of lipid metabolism, resulting in abnormal lipid metabolism and increasing the risk of cardiovascular diseases. As a vital component of the human body, cardiovascular dysfunction not only causes discomfort such as chest tightness, dizziness, and fatigue, but long-term development can also induce diseases such as hypertension, hyperlipidemia, atherosclerosis, coronary heart disease, and insufficient blood supply to the brain, seriously threatening health. Currently, there are many products targeting cardiovascular protection and lipid regulation, but some products have complex ingredients, single targets, and contain chemical additives, which may cause toxic side effects with long-term use, failing to meet people's needs for safe, gentle, and long-lasting regulation.

[0003] Food-medicine homology substances, possessing both the safety of food and the conditioning effects of traditional Chinese medicine, have become an important direction for the research and development of functional foods. In the traditional Chinese medicine theory system, cardiovascular discomfort and dyslipidemia are closely related to "phlegm and dampness accumulation, turbid lipid stagnation, failure of clear yang to ascend, and failure of turbid yin to descend." Traditional Chinese medicine conditioning takes "ascending clear yang and descending turbid yin, removing phlegm and dampness, and resolving turbidity and lowering lipids" as its core idea. By regulating the functions of the body's internal organs, it improves lipid metabolism from the root and protects cardiovascular function. Summary of the Invention

[0004] To address the aforementioned problems, this invention provides a medicinal and edible homologous composition with cardiovascular protective function and its preparation method. The composition provided by this invention consists entirely of medicinal and edible homologous substances, with mild effects and no toxic side effects. Furthermore, this formula follows the principle of ascending clear qi and descending turbid qi, allowing clear yang to ascend and turbid yin to descend, thus eliminating phlegm, dampness, and lipid turbidity. It has a very good conditioning effect on people with internal phlegm and dampness and turbid lipid obstruction, improving lipid metabolism and protecting cardiovascular function.

[0005] To achieve the above objectives, the present invention provides the following technical solution: This invention provides a food-medicine composition with cardiovascular protective function, comprising kudzu root, cassia seed, lotus leaf, and poria cocos.

[0006] Preferably, the amount of each raw material in the composition is 30g of kudzu root, 3g of cassia seed, 3g of lotus leaf, and 5g of Poria cocos.

[0007] The present invention also provides a method for preparing the composition described in the above technical solution, comprising the following steps: 1) Soak the kudzu root, cassia seed, lotus leaf, and poria cocos in water to obtain a soaking material; 2) Boil the soaking material obtained in step 1), and dry the resulting decoction to obtain the composition.

[0008] Preferably, the total mass ratio of kudzu root, cassia seed, lotus leaf, and poria cocos to water in step 1) is 1:10.

[0009] Preferably, the soaking time in step 1) is 2 hours.

[0010] Preferably, the conditions for decocting in step 2) include: decocting twice, for 30 minutes each time.

[0011] Preferably, the drying conditions in step 2) include: combining the decoctions obtained from two decoctions and filtering them, concentrating the filtrate to obtain an extract, and drying the extract at 60°C to a constant weight to obtain the composition.

[0012] The present invention also provides the application of the composition described above in the preparation of products with cardiovascular protective function.

[0013] The present invention also provides a composition for protecting cardiovascular function, comprising the composition described above and food-acceptable excipients.

[0014] Preferably, the dosage form of the composition includes decoction, granules, pills or capsules.

[0015] Kudzu root, sweet, pungent, and cool in nature, promotes the upward movement of clear yang, invigorates the spleen and stomach qi, and dilates cardiovascular vessels. Cassia seed, bitter, sweet, and slightly cold in nature, clears the liver and improves eyesight, moistens the intestines and promotes bowel movements, and effectively lowers blood lipids. These two herbs, one ascending and one descending, regulate qi and together serve as the principal herbs. Lotus leaf, bitter, astringent, and neutral in nature, promotes the upward movement of clear yang, eliminates dampness and turbidity, and can "lighten the body" and lower lipids. It assists cassia seed in eliminating turbidity and assists kudzu root in ascending clear yang, serving as the assistant herb. Poria, sweet, bland, and neutral in nature, strengthens the spleen, eliminates dampness, calms the mind, and soothes the nerves. Dampness is the source of turbid lipids; strengthening the spleen eliminates dampness and reduces turbidity. It eliminates dampness without harming the body's vital energy and calms the mind to protect blood vessels, serving as the adjuvant herb. The entire formula is based on the principle of ascending clear yang and descending turbid yin, allowing clear yang to ascend and turbid yin to descend, thus eliminating phlegm, dampness, and turbid lipids.

[0016] Beneficial effects: The compositions provided by this invention are all made from substances that are both food and medicine, with mild effects and no toxic side effects. Furthermore, this formula follows the principle of ascending clear qi and descending turbid qi, allowing clear yang to rise and turbid yin to descend, thus eliminating phlegm, dampness, and lipid turbidity. It has a very good conditioning effect on people with internal phlegm and dampness and turbid lipid stagnation, improving blood lipid metabolism and protecting cardiovascular function. Attached Figure Description

[0017] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0018] Figure 1The effect of the composition on body weight changes in atherosclerotic mice; *P<0.05, **P<0.01, compared with the control group; #P<0.05, ##P<0.01, compared with the model group; Figure 2 The effect of the composition on blood lipid levels in atherosclerotic mice; *P<0.05, **P<0.01, compared with the control group; #P<0.05, ##P<0.01, compared with the model group; Figure 3 The effect of the composition on vascular endothelial injury factor and adhesion factor in atherosclerotic mice; *P<0.05, **P<0.01, compared with the control group; #P<0.05, ##P<0.01, compared with the model group; Figure 4 The effect of the composition on the expression levels of AIM2, Caspase-1, GSDMD, and IL-1β mRNA in atherosclerotic mice; *P<0.05, **P<0.01, compared with the control group; #P<0.05, ##P<0.01, compared with the model group; Detailed Implementation

[0019] This invention provides a composition with cardiovascular protective function, comprising kudzu root, cassia seed, lotus leaf, and poria cocos. In this invention, the dosage of each ingredient in the composition is 30g of kudzu root, 3g of cassia seed, 3g of lotus leaf, and 5g of poria cocos. Preferably, the sources of the ingredients in this invention are: poria cocos selected from authentic medicinal materials; and kudzu root, cassia seed, and lotus leaf selected from commercially available medicinal materials.

[0020] The present invention also provides a method for preparing the composition described in the above technical solution, comprising the following steps: 1) Soak the kudzu root, cassia seed, lotus leaf, and poria cocos in water to obtain a soaking material; 2) Boil the soaking material obtained in step 1), and dry the resulting decoction to obtain the composition.

[0021] This invention involves soaking a mixture of kudzu root, cassia seed, lotus leaf, and poria cocos with water to obtain a soaking solution. In this invention, the preferred mass ratio of the total mass of kudzu root, cassia seed, lotus leaf, and poria cocos to water is 1:10. The preferred soaking time is 2 hours.

[0022] This invention involves decocting the obtained soaking material, drying the resulting decoction, and obtaining a composition. Preferably, the decoction conditions include: decocting twice, 30 minutes each time. Preferably, the drying conditions include: combining the decoctions obtained from the two decoctions, filtering, concentrating the filtrate to obtain an extract, and drying the extract at 60°C to constant weight to obtain the composition.

[0023] The present invention also provides the application of the composition described above in the preparation of products with cardiovascular protective function.

[0024] This invention also provides a composition with cardiovascular protective function, comprising the composition described above and food-grade excipients. In this invention, the dosage form of the composition preferably includes decoctions, granules, pills, or capsules. This invention does not impose any particular limitation on the preparation method of the above-mentioned decoctions, granules, pills, or capsules; conventional preparation methods are acceptable.

[0025] To further illustrate the present invention, the following detailed description is provided in conjunction with embodiments, but these should not be construed as limiting the scope of protection of the present invention.

[0026] Example A food-medicine composition with cardiovascular protective function and its preparation method comprises the following steps: 1) Mix the total mass of 30g kudzu root, 3g cassia seed, 3g lotus leaf, and 5g Poria cocos with water at a mass ratio of 1:10 and soak for 2 hours to obtain the soaking material; 2) The soaking material obtained in step 1) is decocted, and the resulting decoction is dried to obtain the composition; wherein, the decoction is decocted twice, each time for 30 minutes; the decoctions obtained from the two decoctions are combined and filtered, and the filtrate is concentrated by a rotary evaporator to obtain an extract. The extract is placed in a 60°C oven and dried to constant weight to obtain the composition.

[0027] Functional verification test The powdered composition prepared in the examples was mixed with purified water to prepare a solution with a concentration of 210 mg / mL; atorvastatin calcium tablets, 10 mg / tablet, were mixed with purified water to prepare a solution with a concentration of 0.13 mg / mL; high-fat feed D12492 [60% fat and 20% carbohydrates (kcal / 100g), D12492] (Nanjing Xiehe).

[0028] Eighteen healthy male SPF-grade ApoE- / - mice, each weighing (20±5) g and aged 7-8 weeks, were used. After one week of acclimatization, an atherosclerosis model was established by feeding them a high-fat diet. After 12 weeks, the atherosclerotic mice were randomly divided into groups of 6 mice each. The control group consisted of C57BL / 6 mice, which received normal drinking water and were administered the same volume of aqueous solution as the drug group daily via gavage. The model group consisted of ApoE- / - mice, which received a high-fat diet, normal drinking water, and were administered the same volume of aqueous solution as the drug group daily via gavage. The drug group consisted of ApoE- / - mice, which received a high-fat diet, normal drinking water, and were administered 0.2 mL of the drug solution daily via gavage. This gavage treatment continued for 12 weeks. At the end of the 12th week, after the final gavage, the mice were fasted overnight, weighed, and blood was collected by enucleation. Serum and tissue samples were collected for subsequent analysis.

[0029] Indicator Testing: 1. Changes in body weight in mice with atherosclerosis After the intervention with the composition, the weight of the mice was measured and recorded every 2 weeks, and the observation continued until the 12th week, for a total of 6 weight measurements. The weight change trend of the mice during the administration of the atherosclerotic drug was systematically recorded.

[0030] 2. Detection of blood lipid levels in atherosclerotic mice After administration, mice were sampled and blood was collected. After standing at room temperature for 4 hours, the sample was centrifuged at 3000 r / min for 10 min and the supernatant was collected. Blood lipid parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), were measured using a fully automated biochemical analyzer.

[0031] 3. Detection of peripheral blood cytokines Whole blood was collected and centrifuged at 3000 r / min for 15 min, and serum was collected. The concentrations of atherosclerosis-related markers ET-1, GM-CSF, and ICAM-1 in the serum were measured according to the ELISA kit instructions.

[0032] 4. qPCR detection of the expression levels of atherosclerosis-related mRNAs AIM2, Caspase-1, GSDMD, and IL-1β. The thoracic aorta was minced and thoroughly ground in liquid nitrogen. 1 mL of TRIzol reagent was added, and the mixture was homogenized. Total RNA was extracted, and the RNA was reverse transcribed into cDNA using a reverse transcription kit. cDNA was then amplified using a SYBR Green qPCR kit. GAPDH was used as an internal control gene. The mRNA level of the target gene was measured using 2... -△△Ct Relative quantitative analysis was performed using this method. Primer sequences are shown in Table 1.

[0033] Table 1 Primer sequences Results and Analysis: (1) Effect of the composition on body weight changes in atherosclerotic mice Figure 1 Data showed that the weight of mice after modeling was significantly higher than that of the Control group. After intervention with the composition, the weight of the Drug group decreased, indicating that the composition may regulate weight through lipid metabolism.

[0034] (2) Effect of the composition on blood lipid levels in atherosclerotic mice according to Figure 2 It was found that the levels of total cholesterol (TC), total triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in the serum of mice in the Model group were significantly increased, while the level of high-density lipoprotein cholesterol (HDL-C) was significantly decreased. Compared with the Model group, the levels of serum TC, TG, and LDL-C in mice in the Drug group were significantly decreased, while the level of serum HDL-C was significantly increased. Based on the above results, it can be concluded that the composition has the effect of improving blood lipids.

[0035] (3) Effects of the composition on vascular endothelial injury factors and adhesion factors in atherosclerotic mice Figure 3 Data showed that compared with the control group, the levels of ET-1, GM-CSF, and ICAM-1 in the model group mice were significantly increased. After intervention with the composition, the levels of ET-1, GM-CSF, and ICAM-1 were significantly reduced compared with the model group, indicating that the composition can effectively improve vascular endothelial damage in atherosclerotic mice, inhibit the expression of vascular adhesion molecules, and exert an anti-atherosclerotic effect.

[0036] (4) Effects of the composition on the expression levels of AIM2, Caspase-1, GSDMD, and IL-1β mRNA in atherosclerotic mice Figure 4Data showed that, compared with the control group, the expression of AIM2, Caspase-1, GSDMD, and IL-1β mRNA was increased in the model group; compared with the model group, the expression of AIM2, Caspase-1, GSDMD, and IL-1β mRNA was decreased in the drug group, indicating that the composition can downregulate the expression of AIM2 inflammasome and pyroptosis-related genes in atherosclerotic mice, and alleviate vascular inflammation and pyroptosis.

[0037] In summary, the composition can regulate the body weight of atherosclerotic mice, improve lipid metabolism disorders, reduce serum total cholesterol, total triglycerides, and low-density lipoprotein cholesterol levels while increasing high-density lipoprotein cholesterol levels, repair vascular endothelial damage, inhibit the expression of vascular adhesion molecules, downregulate the expression of AIM2 inflammasome and pyroptosis-related gene mRNA, and alleviate vascular inflammation and pyroptosis, thereby exerting an anti-atherosclerotic effect.

[0038] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A food-medicine composition with cardiovascular protective function, characterized in that, Including kudzu root, cassia seed, lotus leaf, and Poria cocos.

2. The composition according to claim 1, characterized in that, The dosage of each ingredient in the composition is as follows: 30g of kudzu root, 3g of cassia seed, 3g of lotus leaf, and 5g of Poria cocos.

3. A method for preparing the composition according to claim 1 or 2, characterized in that, Includes the following steps: 1) Soak the kudzu root, cassia seed, lotus leaf, and poria cocos in water to obtain a soaking material; 2) Boil the soaking material obtained in step 1), and dry the resulting decoction to obtain the composition.

4. The preparation method according to claim 3, characterized in that, Step 1) The total mass ratio of kudzu root, cassia seed, lotus leaf, and poria cocos to water is 1:

10.

5. The preparation method according to claim 3, characterized in that, The soaking time in step 1) is 2 hours.

6. The preparation method according to claim 3, characterized in that, Step 2) The conditions for decocting include: decocting twice, 30 minutes each time.

7. The preparation method according to claim 3, characterized in that, Step 2) The drying conditions include: combining the decoctions obtained from two decoctions and filtering them, concentrating the filtrate to obtain an extract, and drying the extract at 60°C to constant weight to obtain the composition.

8. The use of the composition according to claim 1 or 2 in the preparation of a product having cardiovascular protective function.

9. A composition having cardiovascular protective function, comprising the composition of claim 1 or 2 and a food-acceptable excipient.

10. The composition according to claim 9, characterized in that, The dosage form of the composition includes decoction, granules, pills or capsules.

Images